Q-omics provides the consensus-scored TUSC1 profile across patient tissues and cancer cell-line models. TUSC1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, TUSC1 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, TUSC1 RNA expression shows 16,918 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, THCA, and THYM as cancer lineages where TUSC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TUSC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TUSC1 survival associations across molecular data types. TUSC1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TUSC1 RNA expression–survival associations across cancer types. High TUSC1 expression shows unfavorable associations in KIRP, ACC and LIHC, but favorable associations in MESO, KIRC and UVM. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for TUSC1 RNA expression.
This table summarizes TUSC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TUSC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TUSC1 shows lower tumor expression in THCA, LUAD, UCEC and COAD and higher tumor expression in HNSC and KIRC. The THCA box plot shows higher TUSC1 RNA expression in normal versus tumor tissue (log2 FC = −0.905, t-test p < 0.001).
This table shows molecular features associated with TUSC1 in patient tissues and cancer cell lines. In patient samples, TUSC1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TUSC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
